Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Monopar Therapeutics is a clinical-stage biopharmaceutical company developing proprietary therapeutics for cancer patients. The company's lead programs include MNPR-101 (camsirubicin) for advanced solid tumors and MNPR-202 for radiotherapy-induced severe oral mucositis. With zero revenue, a strong balance sheet (56.1x current ratio), and negative cash burn, the stock trades on clinical trial milestones and partnership potential.
Monopar operates as a clinical-stage development company with no current revenue generation. The business model relies on advancing drug candidates through FDA clinical trials (Phase 1/2/3) to demonstrate safety and efficacy, then either commercializing approved products directly or partnering with larger pharmaceutical companies for licensing fees, milestone payments, and royalties. Value creation depends entirely on clinical trial success rates, regulatory approval probability, and market exclusivity through patents. The company's exceptionally strong current ratio (56.1x) indicates substantial cash runway to fund operations without immediate financing needs, though negative operating cash flow reflects ongoing R&D burn.
Clinical trial data readouts and interim analysis results for MNPR-101 and MNPR-202 programs
FDA regulatory decisions including IND approvals, Fast Track designations, and Breakthrough Therapy status
Partnership announcements or licensing deals with major pharmaceutical companies
Cash runway updates and financing activities (equity raises, debt facilities)
Competitive clinical data from rival oncology programs targeting similar indications
Biotech sector sentiment and risk appetite for pre-revenue clinical assets
Binary clinical trial outcomes with high failure rates (historically ~90% of oncology drugs fail to reach approval), creating total loss potential
Regulatory pathway uncertainty as FDA requirements for accelerated approval and surrogate endpoints continue evolving, particularly for oncology indications
Patent cliff risk if clinical development timelines consume significant patent life before commercialization, reducing market exclusivity period
Healthcare pricing pressure from government negotiation policies (IRA drug pricing provisions) reducing future revenue potential for approved products
Large pharmaceutical companies and well-funded biotechs developing competing oncology therapeutics with superior efficacy or safety profiles
Rapid advancement in immuno-oncology and targeted therapies potentially rendering small molecule approaches obsolete for certain indications
Partnership dependency risk - inability to secure pharma partnerships could force capital-intensive solo commercialization or asset sales at unfavorable valuations
Equity dilution risk from future financing rounds required to fund clinical trials through approval, particularly if conducted at depressed valuations
Cash runway constraints if clinical trials experience delays or require expansion, potentially forcing financing at inopportune times
Negative ROE (-25.7%) and ROA (-13.5%) reflecting ongoing losses, though typical for pre-revenue stage - risk is prolonged value destruction if milestones slip
low - Pre-revenue biotechs are largely insulated from GDP fluctuations as they generate no sales tied to economic activity. However, capital markets access is cyclically sensitive: risk-on environments improve equity financing terms while recessions tighten venture capital and public market funding. Clinical trial costs remain fixed regardless of economic conditions, though patient recruitment can be marginally affected by healthcare utilization patterns.
Rising interest rates negatively impact valuation through two mechanisms: (1) higher discount rates applied to distant future cash flows reduce NPV of pipeline assets, particularly severe for clinical-stage companies with 5-10 year commercialization timelines, and (2) rates affect relative attractiveness versus fixed income, causing capital rotation away from speculative growth assets. The company's zero debt means no direct financing cost impact, but equity financing becomes more expensive as investor required returns increase.
Minimal direct credit exposure given zero debt and strong liquidity position. However, credit market conditions indirectly affect partnership economics - pharmaceutical companies facing tighter credit may reduce business development spending and offer less favorable licensing terms. Venture debt availability as a non-dilutive funding option also depends on credit market functioning.
growth - Attracts speculative growth investors and biotech specialists willing to accept binary risk/reward profiles in exchange for potential multi-bagger returns from successful drug approvals. High volatility (evidenced by -33.2% 3-month return despite +65.6% 6-month return) appeals to momentum traders around catalyst events. Not suitable for value or income investors given zero revenue, negative earnings, and no dividend. Institutional ownership likely concentrated among healthcare-focused hedge funds and venture capital rather than broad index funds.
high - Extreme volatility characteristic of clinical-stage biotechs, with stock price driven entirely by binary clinical and regulatory events rather than fundamental earnings. Recent performance shows 98.8 percentage point swing between 3-month (-33.2%) and 6-month (+65.6%) returns, indicating event-driven price action. Small market cap ($0.4B) amplifies volatility through limited float and liquidity. Expect continued high beta to biotech sector indices and sharp reactions to trial data releases.
